Fernandez Maria M, Coeytaux Francine, de León Rodolfo Gomez Ponce, Harrison Denise L
Product Promotion and Distribution Unit, Ipas, Chapel Hill, North Carolina, USA.
Int J Gynaecol Obstet. 2009 May;105(2):180-6. doi: 10.1016/j.ijgo.2008.12.016. Epub 2009 Mar 14.
To assess the worldwide availability of misoprostol. Documenting the extent of misoprostol use in obstetrics-gynecology is difficult because the drug typically is unregistered for such indications.
Data for 2002-2007 on annual sales (measured in weight) to hospitals and retail pharmacies, plus manufacturer prices per 200-microg misoprostol, were analyzed for medications containing misoprostol alone or combined with a nonsteroidal anti-inflammatory drug (NSAID); regional and country-specific trends were identified. Consumer prices per pill are documented for all formulations of registered medications.
Of the misoprostol sold worldwide, 70% was misoprostol-NSAID-combination drugs; of this, 91% was sold in North America and Western Europe. Asia sold the most misoprostol-only drugs; sales increased dramatically in Bangladesh (by 128%) and India (646%), where various low-price brands are sold. Misoprostol sales decreased in Latin America but increased in the Middle East-North Africa and Sub-Saharan Africa; these regions generally had low amounts sold per population.
Availability is improving in some low-income regions where misoprostol could significantly reduce maternal deaths due to postpartum hemorrhage and unsafe abortion.
评估米索前列醇在全球的可及性。记录米索前列醇在妇产科的使用程度很困难，因为该药物通常未针对此类适应症进行注册。
分析了2002年至2007年向医院和零售药店的年度销售数据（以重量计），以及每200微克米索前列醇的制造商价格，这些数据涉及仅含米索前列醇或与非甾体抗炎药（NSAID）联合使用的药物；确定了区域和国家特定的趋势。记录了所有注册药物制剂的每片消费者价格。
在全球销售的米索前列醇中，70%是米索前列醇与非甾体抗炎药的联合药物；其中，91%在北美和西欧销售。亚洲销售的仅含米索前列醇的药物最多；孟加拉国（增长128%）和印度（增长646%）的销量大幅增加，在这些国家销售各种低价品牌。拉丁美洲的米索前列醇销量下降，但中东 - 北非和撒哈拉以南非洲的销量增加；这些地区的人均销量普遍较低。
在一些低收入地区，米索前列醇的可及性正在改善，在这些地区，米索前列醇可显著降低产后出血和不安全堕胎导致的孕产妇死亡。
